Mesoblast (ASX:MSB)
ASX announcement history & article coverage
Transparent by design.
Announcments by Mesoblast (ASX:MSB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year
Mesoblast reports US$115M full-year revenue for Ryoncil® with strong growth outlook
Receives FDA BLA Filing Number and Requests Modular Review
Mesoblast Receives FDA BLA Filing Number for Rexlemestrocel-L in End-Stage Heart Failure Patients with LVADs
Becoming a substantial holder
Ceasing to be a substantial holder
Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility
Mesoblast draws US$50 million from five-year non-dilutive facility to retire short-term debt
Becoming a substantial holder
Ceasing to be a substantial holder
ASX CEO Connect Presentation
Quarterly Activities/Appendix 4C Cash Flow Report
Mesoblast reports US$30.3M Ryoncil® revenues, achieves Phase 3 recruitment target, and advances cell therapy pipeline
Patient Recruitment Target Achieved in CLBP Pivotal Trial
Mesoblast completes patient recruitment for Phase 3 trial of rexlemestrocel-L in chronic low back pain
Appendix 3Y for Gregory George
Notification of cessation of securities - MSB
Notification regarding unquoted securities - MSB
Application for quotation of securities - MSB
Notification regarding unquoted securities - MSB
Acquires CAR Platform for Precision-Enhanced Cell Products
Mesoblast acquires exclusive CAR platform license to enhance MSC therapies for inflammatory diseases
